Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib and everolimus may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving erlotinib together with everolimus may kill more
tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving erlotinib
together with everolimus and to see how well it works in treating patients with metastatic
breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Erlotinib Hydrochloride Everolimus Protein Kinase Inhibitors Sirolimus